Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Libby MD
Peter Libby MD Advisory Board
James Udelson MD
James E. Udelson MD Advisory Board
Deepak Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI Advisory Board
See All Experts
featured
Published in Cardiology

Expert Opinion / Commentary · December 13, 2017

2017 Top Stories in Cardiology: Novel Therapies Plumb the Depths of Cholesterol and Can Improve Cardiovascular Outcomes

Peter Libby MD
Written by
Peter Libby MD

 

 Save  Recommend
 Share

Additional Info

  1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722.
  2. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633-643.
  3. Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2(5):547-555.
  4. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971.
  5. Libby P. Commentary On: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. PracticeUpdate [Internet]. 2017; (2017).
  6. Libby P. Commentary On: Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. PracticeUpdate [Internet]. 2017; 2017.
  7. Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527-1539.
  8. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440.
  9. Jarcho JA, Keaney JF Jr. Proof that lower is better - LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372(25):2448-2450.

Disclosure statements are available on the authors' profiles:

Peter Libby MD

Further Reading

Most Read This Week

Recently Updated